Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ambrisentan + tadalafil + treprostinil
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A triple combination therapy used for treating severe pulmonary arterial hypertension (PAH). This combination targets multiple pathways involved in PAH pathophysiology: ambrisentan blocks endothelin receptor type A, tadalafil inhibits phosphodiesterase type 5, and treprostinil acts as a prostacyclin analogue promoting vasodilation and inhibiting platelet aggregation. Clinical studies have shown significant improvements in hemodynamics, right ventricular structure and function, and functional status in patients with severe PAH.
02
Targets
EDNRA (Endothelin receptor type A)EDNRB (Endothelin receptor type B)PPARD (Peroxisome proliferator–activated receptor delta)PDE5 (Phosphodiesterase 5A)PTGIR (Prostanoid IP Receptor)PTGDR (Prostanoid DP1 receptor)PTGER2 (Prostaglandin E2 receptor EP2)
Beyond the preview
Go deeper on ambrisentan + tadalafil + treprostinil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ambrisentan + tadalafil + treprostinil.